3,958 results match your criteria Plaque Psoriasis


Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis.

Indian Dermatol Online J 2019 Jan-Feb;10(1):76-78

Department of Dermatology, Command Hospital, Kolkata, West Bengal, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_170_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362754PMC
February 2019

Apremilast in Psoriasis and Beyond: Big Hopes on a Small Molecule.

Indian Dermatol Online J 2019 Jan-Feb;10(1):1-12

Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_437_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362739PMC
February 2019

Dermoscopic Features of Psoriasis, Lichen Planus, and Pityriasis Rosea in Patients With Skin Type IV and Darker Attending the Regional Dermatology Training Centre in Northern Tanzania.

Dermatol Pract Concept 2019 Jan 31;9(1):44-51. Epub 2019 Jan 31.

Public, Private, and Teaching Practice of Dermatology, Konstanz, Germany.

Background: Papulosquamous skin diseases can be challenging to diagnose, especially in dark skin. Dermoscopy is reported to be helpful, but few data are available on its use in skin type IV or darker.

Objective: To describe dermoscopic features in plaque-type psoriasis (PP), lichen planus (LP), and pityriasis rosea (PR) patients attending the Regional Dermatology Training Centre in Moshi, Northern Tanzania, and to compare findings with published data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5826/dpc.0901a11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368079PMC
January 2019

Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation.

J Eur Acad Dermatol Venereol 2019 Feb 15. Epub 2019 Feb 15.

Department of Advanced Biomedical Sciences, University of Naples "Federico II", Italy.

Background/objective: Although 40% of psoriasis patients reported skin pain, this symptom is often underestimated. A new formula of calcipotriol plus betamethasone dipropionate (Cal/BD) has been recently approved for psoriasis treatment. Therefore, we aimed to evaluate the efficacy of Cal/BD aerosol foam on skin pain of patients with plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15488DOI Listing
February 2019

Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.

Drug Dev Ind Pharm 2019 Feb 14:1-13. Epub 2019 Feb 14.

a Department of Pharmaceutics , National Institute of Pharmaceutical Education & Research (NIPER) , Hyderabad , India ;

Objective: The aim of this study was to formulate nanostructured lipid carriers (NLCs) of dithranol-loaded in gel for ease of application and to evaluate its anti-psoriatic efficacy vis-a-vis conventional ointment formulation.

Significance: This study will provide an insight about the use of nanocarriers, esp. NLCs loaded with dithranol for the effective treatment of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03639045.2019.1576722DOI Listing
February 2019
2.006 Impact Factor

Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Open-label extension of the NOR-SWITCH trial.

J Intern Med 2019 Feb 14. Epub 2019 Feb 14.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo.

Background And Objectives: The 52-week, randomized, double blind, non-inferiority, government funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with infliximab originator. The NOR-SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT-P13 throughout the 78-week study period (maintenance group) vs patients switched to CT-P13 at week 52 (switch group).

Primary Outcome: disease worsening during follow-up based on disease specific composite measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/joim.12880DOI Listing
February 2019
1 Read

Hidden treasures: Exploring selective publication of trials and trial outcomes in biologic treatment for plaque psoriasis.

Br J Dermatol 2019 Feb 13. Epub 2019 Feb 13.

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Studies with statistically significant positive results are more likely to be published than studies with negative or inconclusive results (1). An example in dermatology were the studies with imiquimod for viral warts, which were 'negative' but never published by the funding pharmaceutical companies (2). By comparing published data to publically accessible data held by the Food and Drug Administration (FDA), Turner et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17773DOI Listing
February 2019

Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.

J Dermatolog Treat 2019 Feb 12:1-35. Epub 2019 Feb 12.

a Celgene Corporation , Summit , NJ.

Background: Pruritus is a prevalent and bothersome symptom of scalp psoriasis. Validated scales assessing scalp itch are needed to assess treatment efficacy.

Objective: To evaluate comprehensibility and reproducibility of the Scalp Itch Numeric Rating Scale (NRS), a novel scale being used in a phase 3 study of apremilast. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1577546DOI Listing
February 2019

The Relationship between HLA-B27, HLA-Cw06, HLA-DR7 and Psoriatic Arthritis in Vietnamese Patients: Disease Progression and Therapeutic Burden.

Open Access Maced J Med Sci 2019 Jan 27;7(2):300-301. Epub 2019 Jan 27.

University of Rome G. Marconi, Rome, Italy.

We conducted a prospective, cross-sectional study at Ho Chi Minh City Hospital of Dermato Venereology from January 2016 to March 2017 in 40 psoriatic arthritis (PsA) patients to evaluate the disease progression and therapeutic burden about the HLA patterns. Based upon our results, PsA with HLA-B27 (+) had a threat of severe arthritis. PsA with HLA-Cw06 (+) had a higher risk of earlier onset and shorter duration for plaque psoriasis to transform into PsA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364717PMC
January 2019
1 Read

Successful Psoriasis Treatment Using NB-UVB with Methotrexate: The Vietnamese Experience.

Open Access Maced J Med Sci 2019 Jan 27;7(2):253-255. Epub 2019 Jan 27.

University of Rome G. Marconi, Rome, Italy.

Aim: To compare the effectiveness of narrowband ultraviolet B (NBUVB) and oral methotrexate (MTX) to oral MTX alone in Vietnamese psoriasis patients, from May 2016 to May 2018.

Methods: We conducted a non-randomized trial on 70 patients with plaque-type psoriasis of moderate to severe. Thirty-five patients apply NBUVB once/day in 5 days/week for 4 weeks plus oral MTX 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364742PMC
January 2019

Efficacy of Narrow - Band UVB Phototherapy versus PUVA Chemophototherapy for Psoriasis in Vietnamese Patients.

Open Access Maced J Med Sci 2019 Jan 25;7(2):227-230. Epub 2019 Jan 25.

University of Rome G. Marconi, Rome, Italy.

Background: Psoralen UVA (PUVA) and narrow-band UVB (NBUVB) chemophototherapy are treatment options for psoriasis.

Aim: To compare the effectiveness of NBUVB with PUVA in Vietnamese psoriasis patients.

Methods: We conducted a non-randomized trial on 60 patients with plaque-type psoriasis (30 NBUVB, 30 PUVA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364720PMC
January 2019

Treating to Target(s) With Interleukin-17 Inhibitors.

J Cutan Med Surg 2019 Feb 11:1203475418824565. Epub 2019 Feb 11.

12 University of Alberta, Edmonton, AB, Canada.

Background:: The treat-to-target (T2T) strategy has become established in several medical specialties as a key guidance to optimal therapeutic decision making. T2T may be effective in the assessment of the biologic class of agents called interleukin (IL)-17 inhibitors, which are emerging as a safe and effective treatment option for autoimmune inflammatory conditions such as plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).

Objective:: The objective of this article is to use a T2T approach for the evaluation of the effectiveness and safety of IL-17 inhibitors in the management of patients with plaque psoriasis, PsA, and AS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418824565DOI Listing
February 2019
1 Read

Interleukin-18 exacerbates skin inflammation and affects microabscesses and scale formation in an imiquimod-induced mouse model of psoriasis.

Chin Med J (Engl) 2019 Feb 5. Epub 2019 Feb 5.

Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.

Background: As a potent pro-inflammatory cytokine of the interleukin (IL)-1 family, IL-18 was elevated in early active and progressive plaque-type psoriatic lesions and that serum or plasma levels of IL-18 correlated with the Psoriasis Area and Severity Index (PASI). Although results from previous studies have established that IL-18 may aggravate psoriatic inflammation, the mechanisms of this process remain unknown. In this study, IL-18 knock out (KO) mice and Wild-type (WT) mice were used to investigate the effects of IL-18 within a mouse model of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000140DOI Listing
February 2019

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.

Drug Saf 2019 Feb 9. Epub 2019 Feb 9.

Department of Dermatology, University of Connecticut Health Center, 21 South Road, 2nd Floor, Farmington, CT, 06030, USA.

Introduction: Theoretical risks of biologic agents remain under study.

Objective: The aim of this study was to integrate 1-year safety data from 12 ustekinumab registrational trials.

Methods: Patients had moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA) (± methotrexate), or moderate-to-severe Crohn's disease (CD; failed/intolerant of immunomodulators/corticosteroids). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-019-00797-3DOI Listing
February 2019
2 Reads

Long-term, real world, efficacy of biologics for psoriasis: a single centre's experience.

Br J Dermatol 2019 Feb 9. Epub 2019 Feb 9.

The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, M6 8HD, UK.

Biologic therapies have revolutionised the management of moderate to severe chronic plaque psoriasis and have been life-transforming for many patients. The first biologic to be licensed for psoriasis in the UK was efalizumab in 2004 and there are now nine licensed by the European Medicines Agency for the indication of moderate-severe disease. A key determinant in choosing a biologic for an individual patient is the likelihood of long-term efficacy and for some there is compelling evidence that monotherapy can result in long-term disease control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17756DOI Listing
February 2019

Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation.

J Eur Acad Dermatol Venereol 2019 Feb 8. Epub 2019 Feb 8.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Department of Dermatology, Venerology und Allergy, Division of Evidence-Based Medicine (dEBM).

Twenty percent of patients with plaque psoriasis also have psoriatic arthritis - a disease affecting joints and entheses. Different treatment options exist but currently no succinct systematic overview exists. A systematic review of approved systemic treatments for psoriatic arthritis was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15482DOI Listing
February 2019
2 Reads

Subclinical atherosclerosis in psoriasis. Usefulness of femoral artery ultrasound for the diagnosis, and analysis of its relationship with insulin resistance.

PLoS One 2019 8;14(2):e0211808. Epub 2019 Feb 8.

Department of Gastroenterology, University Hospital San Cecilio, Granada, Spain.

Background: Psoriasis is associated with an increased risk of cardiovascular disease (CVD) at younger ages that is not identifiable by traditional risk factors. Screening for subclinical atherosclerosis with ultrasound has only been investigated in carotid arteries. Femoral artery ultrasound has never been considered for this purpose. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211808PLOS
February 2019
1 Read

Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Randomised Phase 2 Study.

Br J Dermatol 2019 Feb 7. Epub 2019 Feb 7.

Probity Medical Research, Waterloo, ON, Canada.

Background And Objectives: Inhibiting the interleukin (IL)-23 cytokine in patients with psoriasis has demonstrated high levels of skin clearance. In this Phase 2 (AMAF, NCT02899988), multicentre, double-blind trial, we investigated the efficacy and safety of three dose groups of mirikizumab (LY3074828), a p19-directed IL-23 antibody, compared to placebo in patients with moderate-to-severe plaque psoriasis.

Methods: Adult patients were randomised 1:1:1:1 to receive placebo (N=52), mirikizumab 30 mg (N=51), 100 mg (N=51), or 300 mg (N=51) subcutaneously at Weeks 0 and 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17628DOI Listing
February 2019

Polymorphisms in Corticotrophin-releasing Hormone-proopiomelanocortin (CRH-POMC) System Genes are Associated with Plaque Psoriasis.

Acta Derm Venereol 2019 Feb 6. Epub 2019 Feb 6.

Department of Dermatology and Venerology, University of Tartu, EE-50417 Tartu, Estonia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3137DOI Listing
February 2019

Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.

Cardiovasc Res 2019 Feb 5. Epub 2019 Feb 5.

Section of Inflammation and Cardiometabolic Disease, National Heart, Lung, and Blood Institute; National Institutes of Health, Bethesda, MD, USA.

Aims: The use of biologic therapy has increased over the past decade well beyond primary autoimmune diseases. Indeed, a recent trial using an anti-IL-1beta antibody reduced second myocardial infarction (MI) in those who have had MI. Psoriasis is a chronic inflammatory disease often treated with biologics when severe, is associated with increased risk of MI, in part driven by high-risk coronary plaque phenotypes by coronary computed tomography angiography (CCTA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cvr/cvz009DOI Listing
February 2019
1 Read

Is the routine screening for hyperhomocysteinaemia recommended in patients with chronic plaque psoriasis?

Authors:
P Gisondi

Br J Dermatol 2019 Feb;180(2):262-263

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17357DOI Listing
February 2019

Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy.

BMJ Case Rep 2019 Jan 31;12(1). Epub 2019 Jan 31.

Pathology, Henry Ford Hospital, Detroit, Michigan.

Erythrodermic psoriasis (EP) is the most serious type of psoriasis with high morbidity and mortality. First-line recommended therapies for EP, cyclosporine and infliximab have significant adverse effects. Cyclosporine increases the risk of hypertension, leucopenia, infections and renal failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226959DOI Listing
January 2019
17 Reads

Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.

Ann Dermatol Venereol 2019 Feb 28;146(2):106-114. Epub 2019 Jan 28.

Département de santé publique, CHU d'Ambroise-Paré, Assistance publique-hôpitaux de Paris, 9, avenue Charles de Gaulle, 92104 Boulogne-Billancourt cedex, France.

Background: Methotrexate (MTX) is a major systemic treatment for moderate to severe plaque psoriasis. A randomized trial has recently been published evaluating a single weekly dosage (17.5mg), but few prospective real-life data are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2018.11.011DOI Listing
February 2019
1 Read

Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.

Eur J Gastroenterol Hepatol 2019 Jan 29. Epub 2019 Jan 29.

Gastroenterology and Hepatology Unit, Department of Internal Medicine Department of Dermatology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Aim: Until recently, clinicians caring for patients with psoriasis who were infected with hepatitis C virus (HCV) were concerned that treating one condition could exacerbate the other. We evaluated the outcome of treatment with direct-acting antiviral agents (DAAs) on patients with psoriasis having chronic hepatitis C (CHC) infection.

Patients And Methods: This was an observational prospective cross-sectional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MEG.0000000000001370DOI Listing
January 2019
2.152 Impact Factor

Hodgkin's lymphoma in a patient on adalimumab treatment for psoriasis.

AME Case Rep 2018 24;2:49. Epub 2018 Dec 24.

Dermatology Clinic, King Khalid University Hospital, Riyadh, Saudi Arabia.

Adalimumab is a human monoclonal antibody which targets tumor necrosis factor (TNF)-alpha. It is produced by recombinant DNA technology, using a mammalian cell expression system and is widely-known to treat a number of immune-mediated conditions, including psoriasis. There has been a growing concern regarding the possible association between TNF-alpha inhibitors and malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/acr.2018.12.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327155PMC
December 2018
2 Reads

The Impact of Ramadan Fasting on the Reduction of PASI Score, in Moderate-To-Severe Psoriatic Patients: A Real-Life Multicenter Study.

Nutrients 2019 01 27;11(2). Epub 2019 Jan 27.

Padeh and Ziv Hospitals, Azrieli Faculty of Medicine, Bar-Ilan University, 5290002 Ramat Gan, Israel.

Fasting during the month of Ramadan consists of alternate abstinence and re-feeding periods (circadian or intermittent fasting). Nothing is currently known on the impact of this kind of fasting on psoriasis. A sample of 108 moderate-to-severe plaque psoriasis patients (aged 42. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/nu11020277DOI Listing
January 2019

The impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease.

Arthritis Care Res (Hoboken) 2019 Jan 25. Epub 2019 Jan 25.

University of Ottawa, Faculty of Medicine, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Objective: Psoriatic arthritis (PsA) has a genetic background. Approximately 40% of patients have a family history of psoriasis or PsA, which may affect disease features. The aim of this study was to assess the effects of family history of psoriasis and PsA on disease phenotypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23836DOI Listing
January 2019
6 Reads

Effective treatment of nail psoriasis with apremilast: report of two cases and review of the literature.

Dermatol Online J 2018 Sep 15;24(9). Epub 2018 Sep 15.

Department of Dermatology, Hospital General Universitario de Valencia, Spain.

Nail psoriasis can cause great morbidity and a negative impact on the personal and work-related life of the patients. However, it responds more poorly to most drug therapies. Classically, the first line of treatment for nail psoriasis has been topical medication, but the new biological drugs seem to be the most effective treatment. Read More

View Article

Download full-text PDF

Source
September 2018

Localisation of treatment-resistant areas in patients on biologics.

Br J Dermatol 2019 Jan 24. Epub 2019 Jan 24.

Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Background: Traditionally, psoriasis in certain body sites such as the scalp, nails, palms, soles, and the intertriginous areas has been acknowledged as difficult-to-treat.

Objective: To investigate the body location of treatment-resistant psoriasis in patients treated with biologic agents in real-world clinical practice, and to study the association between localisation and the quality of life.

Methods: In this observational study we investigated the skin and/or nail location of treatment-resistant psoriasis in patients with moderate-to-severe psoriasis treated for > 6 months with biologic agents with a partial or good response to treatment defined as having a PASI ≥ 1 and ≤ 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17689DOI Listing
January 2019
1 Read

Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis.

JCI Insight 2019 Jan 24;4(2). Epub 2019 Jan 24.

Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France.

Psoriasis is one of the most common skin inflammatory diseases worldwide. The vitamin D3 analog calcipotriol has been used alone or in combination with corticosteroids in treating plaque psoriasis, but how it suppresses psoriatic inflammation has not been fully understood. Using an experimental mouse psoriasis model, we show that topical calcipotriol inhibited the pivotal IL-23/IL-17 axis and neutrophil infiltration in psoriatic skin, and interestingly, such effects were mediated through the vitamin D receptor (VDR) in keratinocytes (KCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.123390DOI Listing
January 2019

Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.

J Dermatol 2019 Jan 23. Epub 2019 Jan 23.

The Jikei University School of Medicine, Tokyo, Japan.

Secukinumab, a fully human monoclonal antibody neutralizing interleukin-17A, has been shown to have significant efficacy in the treatment of moderate to severe psoriasis. Long-term (3-year) efficacy and safety of secukinumab in Japanese patients with moderate to severe psoriasis were evaluated in an extension study of a large phase 3 global study (SCULPTURE). In the core study, 52 Japanese patients with 75% improvement of Psoriasis Area and Severity Index (PASI-75) response at week 12 were re-randomized to a fixed interval (FI; every 4 weeks) schedule and retreatment as needed (RAN), in which patients received placebo until start of relapse, at which time secukinumab was reinitiated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14761DOI Listing
January 2019

Institute for clinical and economic review (ICER) psoriasis update 2018: what it means for dermatologists treating moderate-to-severe plaque psoriasis.

J Dermatolog Treat 2019 Jan 22:1-3. Epub 2019 Jan 22.

d Dermatology Research and Education Foundation , Irvine , CA , USA.

Objective: This paper aims to summarize the key findings of the updated report issued in August 2018 by the Institute of Clinical and Economic Review (ICER) regarding the clinical efficacy and budget impact of various immunomodulators.

Methods: This paper specifically focuses on the inclusion of two new biologics, guselkumab and certolizumab in the context of their relative cost-effectiveness using analyses on sequential implementation of specific first- and second-line therapies.

Results: The ICER found that initiating biologic therapy with an IL-17 inhibitor or guselkumab results in the most clinical improvement, but is also associated with higher costs. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1
Publisher Site
http://dx.doi.org/10.1080/09546634.2019.1573307DOI Listing
January 2019
1 Read

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.

Basic Clin Pharmacol Toxicol 2019 Jan 20. Epub 2019 Jan 20.

LEO Pharma A/S, Ballerup, Denmark.

Brodalumab is a fully human monoclonal antibody targeting the IL-17 receptor A leading to an inhibition of the biological effect of IL-17A, IL-17F, IL-17A/F heterodimer, IL-17C and IL-17E isoforms. It has shown to be efficacious in the treatment of moderate to severe plaque psoriasis (210 mg administered subcutaneously at weeks 0, 1 and 2 followed by 210 mg every 2 weeks [Q2W+1]). A population pharmacokinetic model based on psoriasis patients only from six clinical trials was developed to describe the pharmacokinetics and identify sources of variability. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcpt.13202
Publisher Site
http://dx.doi.org/10.1111/bcpt.13202DOI Listing
January 2019
1 Read

Diagnosis and Management of Cutaneous Psoriasis: A Review.

Adv Skin Wound Care 2019 Feb;32(2):58-69

Alisa Brandon, MSc • Medical Student • University of Toronto • Toronto, Ontario, Canada Asfandyar Mufti, MD • Dermatology Resident • University of Toronto • Toronto, Ontario, Canada R. Gary Sibbald, DSc (Hons), MD, MEd, BSc, FRCPC (Med Derm), ABIM, FAAD, MAPWCA • Professor • Medicine and Public Health • University of Toronto • Toronto, Ontario, Canada • Director • International Interprofessional Wound Care Course and Masters of Science in Community Health (Prevention and Wound Care) • Dalla Lana Faculty of Public Health • University of Toronto • Past President • World Union of Wound Healing Societies • Editor-in-Chief • Advances in Skin and Wound Care • Philadelphia, Pennsylvania.

General Purpose: To provide information about the diagnosis and management of cutaneous psoriasis.

Target Audience: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care.

Learning Objectives/outcomes: After completing this continuing education activity, the provider should be better able to: ABSTRACT: Psoriasis is a chronic inflammatory disease that is characterized by plaque, inverse, guttate, pustular, and erythrodermic variants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ASW.0000550592.08674.43DOI Listing
February 2019
3 Reads
1.634 Impact Factor

Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.

J Med Econ 2019 Feb 4:1-7. Epub 2019 Feb 4.

b Health Economics & Outcomes Research, Celgene Corporation , Summit , NJ , USA.

Objective: This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics.

Methods: A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apremilast or biologics between January 1, 2014, and December 31, 2015; had 12 months of pre-index and post-index continuous enrollment in the database; and were biologic-naive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13696998.2019.1571500DOI Listing
February 2019

A case of erythrodermic psoriasis successfully treated with ixekizumab.

Dermatol Ther 2019 Jan 16:e12825. Epub 2019 Jan 16.

Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Erythrodermic psoriasis (EP) is the most severe form of psoriasis, resulting in significant morbidity and mortality. International guidelines on EP treatment are lacking, with most of the biologic drugs being used basing on case reports or small case series. Ixekizumab, a fully human anti-interleukin (IL)-17A monoclonal antibody, is approved for moderate to severe plaque psoriasis while its use in EP is off label. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12825DOI Listing
January 2019
1 Read

Association Between Psoriasis and Dementia: A Population-Based Case-Control Study.

Am J Clin Dermatol 2019 Jan 16. Epub 2019 Jan 16.

Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, 250 Wu-Hsing St., Taipei, 110, Taiwan.

Background: Dementia is a syndrome that involves the deterioration of several higher mental functions in advanced age, and psoriasis is an autoimmune disease characterized by skin plaque. Epidemiological studies have indicated an association between dementia and psoriasis; however, to date, no studies in Asia have reported this association.

Objective: This study used a population-based medical dataset to explore the association between previously diagnosed psoriasis and dementia in Taiwan. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-00420-8
Publisher Site
http://dx.doi.org/10.1007/s40257-018-00420-8DOI Listing
January 2019
11 Reads

Moderate to severe psoriasis: a single-centre analysis of gender prevalence.

G Ital Dermatol Venereol 2019 Jan 15. Epub 2019 Jan 15.

Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy.

Background: Psoriasis is a chronic, relapsing disease and most epidemiological studies include selected patients undergoing systemic therapies only. Epidemiological data suggest that psoriasis affects 2-3% of the general population, and that men and women are equally affected. The objective was to identify differences in gender for disease severity, patient characteristics and comorbidities in patients with moderate to severe psoriasis, independent of therapy. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R23Y9999N00A190
Publisher Site
http://dx.doi.org/10.23736/S0392-0488.18.06200-4DOI Listing
January 2019
4 Reads
0.491 Impact Factor

Effects of Weight Loss on Psoriasis: A Review of Clinical Trials.

Cureus 2018 Oct 24;10(10):e3491. Epub 2018 Oct 24.

Research, Prince Sultan Military Medical City, Riyadh, SAU.

Psoriasis is a chronic autoimmune disease that affects the skin and joints. It typically presents as abnormal skin patches characterized by red, scaly, and very itchy spots. It affects patients in different manners with different severities ranging from small spots or spots that cover a larger area of the skin. Read More

View Article

Download full-text PDF

Source
https://www.cureus.com/articles/10436-effects-of-weight-loss
Publisher Site
http://dx.doi.org/10.7759/cureus.3491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318144PMC
October 2018
5 Reads

Reflectance Confocal Microscopy Features of Plaque Psoriasis Overlap With Horizontal Histopathological Sections: A Case Series.

Am J Dermatopathol 2019 Jan 11. Epub 2019 Jan 11.

Dermatology Clinic, University of Catania, Catania, Italy.

Reflectance confocal microscopy (RCM) displays horizontal, en face tissue sections of the epidermis and upper dermis, and interpretation of its features is classically based on the comparison with vertical conventional histopathological sections that, as known, do not reflect the same plane of observation. In 10 patients affected by psoriasis, we correlated RCM images with horizontal histopathological sections from skin biopsies, observing in all cases marked overlaps between the 2 techniques. Although vertical section examination remains the gold standard for the diagnosis of psoriasis, this novel comparative approach may contribute to a more precise definition of RCM findings and could represent the drive for further research as well as an innovative tool for educational purposes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001297DOI Listing
January 2019
1 Read

Use of fumaric acid derivatives (FADs) in Italian reference centres for psoriasis.

G Ital Dermatol Venereol 2019 Jan 9. Epub 2019 Jan 9.

Centro Studi GISED, Bergamo, Italy.

Background: Several therapies are available for psoriasis, including in some countries oral fumaric acid derivatives (FADs). Even if FADs are not available in the Italian market, they can be prescribed and reimbursed by the National Health Service, on request from the treating physician, when considered as a valuable option in selected patient.

Methods: We performed a retrospective analysis of the PsoReal registry data, restricted to adult psoriatic patients enrolled between 2009 and 2017. Read More

View Article

Download full-text PDF

Source
https://www.minervamedica.it/index2.php?show=R23Y9999N00A190
Publisher Site
http://dx.doi.org/10.23736/S0392-0488.18.06032-7DOI Listing
January 2019
6 Reads

Polymorphisms in IL36G gene are associated with plaque psoriasis.

BMC Med Genet 2019 Jan 11;20(1):10. Epub 2019 Jan 11.

Department of Dermatology and Venerology, University of Tartu, 31 Raja St, 50417, Tartu, Estonia.

Background: Plaque psoriasis is a non-contagious skin disease in which characteristic red and flaky lesions result from a dysregulation involving both innate and adaptive immune mechanisms. Several cytokines have been implicated in these processes and lately interleukin (IL)-36 family members have become more recognised among them. Thus far, genetic studies have only investigated IL36RN gene of this family in relation to pustular psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12881-018-0742-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330488PMC
January 2019
3 Reads

Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis.

Medicine (Baltimore) 2019 Jan;98(2):e14042

Department of Dermatology.

Background: Secukinumab has been approved for the treatment of moderate to severe plaque psoriasis. However, safety measures concerning drug administration is vital during treatment. Understanding the right way to administer drugs is important to reduce any serious adverse drug event. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336633PMC
January 2019
5 Reads

Risankizumab versus ustekinumab for plaque psoriasis: a critical appraisal.

Br J Dermatol 2019 Jan 11. Epub 2019 Jan 11.

Dermatology Centre, Salford Royal Hospital, University of Manchester and the Academic Health Science Centre, Manchester, United Kingdom.

Aim: Gordon et al investigated the efficacy and safety of risankizumab (an anti-interleukin[IL]23p19 biologic) compared with ustekinumab (anti-IL12/23p40) and placebo in patients with moderate-to-severe chronic plaque psoriasis. This is a parallel group controlled study up to 16 weeks with a planned switch of the placebo group to risankizumab at 16 weeks.

Setting And Design: This study consisted of two replicate phase 3, double-blinded randomised-controlled trials (UltIMMa-1 and UltIMMa-2) conducted across 139 centres in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Japan, Mexico, Poland, Portugal, South Korea, Spain and the USA. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjd.17624
Publisher Site
http://dx.doi.org/10.1111/bjd.17624DOI Listing
January 2019
9 Reads

IL28RA inhibits human epidermal keratinocyte proliferation by inhibiting cell cycle progression.

Mol Biol Rep 2019 Jan 10. Epub 2019 Jan 10.

Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, China.

Interleukin (IL) 28 receptor α (IL28RA) is a well-known candidate for psoriasis susceptibility based on previous genome-wide association study (GWAS) analysis. However, the function of IL28RA in psoriasis has not been elucidated. In the present study, the expression of IL28RA was significantly decreased in lesional tissues from patients with plaque psoriasis when compared with the expression observed in adjacent non-lesional tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11033-019-04586-0DOI Listing
January 2019

Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.

J Am Acad Dermatol 2019 Mar 26;80(3):714-721. Epub 2018 Oct 26.

ICON plc, Research Triangle Park, North Carolina.

Background: There is a significant need for novel, safe, and efficacious topical treatments for psoriasis.

Objective: We assessed the safety and efficacy of tapinarof in a new cream formulation at 2 concentrations and with 2 application frequencies in adults with psoriasis.

Methods: Double-blind, vehicle-controlled, randomized, 6-arm trial (1:1:1:1:1:1) in adults, with psoriasis with body surface involvement ≥1% and ≤15% and Physician Global Assessment (PGA) score ≥2 at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.10.037DOI Listing

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: Integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.

Br J Dermatol 2019 Jan 4. Epub 2019 Jan 4.

Medical University of Vienna, Austria.

Tuberculosis (TB) is one of the top ten causes of death worldwide, with approximately 10.0 million active TB cases in 2017 (range 9.0 to 11. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjd.17604
Publisher Site
http://dx.doi.org/10.1111/bjd.17604DOI Listing
January 2019
6 Reads

Acquired Hypertrichosis Localized on a Subsiding Psoriatic Plaque after Plaster Application.

Int J Trichology 2018 Sep-Oct;10(5):229-230

Department of Experimental, Diagnostic and Specialty Medicine, Dermatology Unit, University of Bologna, Bologna, Italy.

Postcast hypertrichosis is a common transient occurrence in orthopedic patients and generally resolves within a few months. Until now, two cases of localized hypertrichosis occurring on more than one pre-existing psoriatic lesions are reported in the literature. We describe the case of a patient who simultaneously developed a single psoriatic plaque and overlying localized hypertrichosis after plaster application. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijt.ijt_50_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290290PMC
January 2019

Ixekizumab for the treatment of psoriasis: an update on new data since first approval.

Expert Rev Clin Immunol 2018 Dec 27:1-11. Epub 2018 Dec 27.

a Copenhagen Research Group for Inflammatory Skin (CORGIS), Department of Dermatology and Allergy, Herlev and Gentofte Hospital , University of Copenhagen , Hellerup , Denmark.

Introduction: Psoriasis is a chronic immune-mediated skin disease with a multifactorial etiology. Studies have shown that the inflammatory cytokine interleukin-17A (IL-17A) is a key mediator in the pathogenesis. Targeted biologics have changed the outcome for patients in a variety of diseases including psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1559730DOI Listing
December 2018
2 Reads